Thrombosis Research

Article	Citations
Is all collagen the same for platelet testing? Editorial on “Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen subs	76
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease	71
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban	56
Corrigendum to “Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation” [Thromb. Res. 229 (2023) 53–68]	56
A novel role of acellular hemoglobin in hemolytic thrombosis	45
Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability	44
PO-08: Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms	41
Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination	41
PO-51: Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery	41
Crosstalk between hemostasis and immunity in cancer pathogenesis	40
Major in-hospital bleeding in patients with pulmonary embolism treated with systemic thrombolysis	39
Linezolid impair proplatelet formation by reducing mitochondrial energy metabolism in MEG-01 cells	37
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	34
PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of superior vena cava syndrome in lung cancer patients	33
DOACs: A perfect fit for patients with bariatric surgery?	32
Predicting post-discharge venous thromboembolism and bleeding among medical patients: External validation of a novel risk score utilizing ubiquitous biomarkers	32
Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study	31
Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms	30
Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors	29
Unveiling the predictive capacity of inflammatory and platelet markers for central retinal artery occlusion	29
Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study	28
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice	28
Regulation of fibrinogen synthesis	28
Investigation of the impact of antithrombin deficiency on the inflammatory response: Results from a single centre cohort study	28
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients	28

Editorial Board	28
Distinct Immunologic Mediators Are Associated with Venous Thromboembolism in Multiply Injured Patients	28
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	26
The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis	26
Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention	26
Isolated subsegmental pulmonary embolism identification based on international classification of diseases (ICD)-10 codes and imaging reports	24
A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres	24
Prosthetic valve dysfunction in patients with mechanical heart valves: Results from the Emergency Salam Centre cohort	24
Myocardial ischemia-reperfusion injury released cellular fibronectin containing domain A (CFN-EDA): A destructive positive loop amplifying arterial thrombosis formation and exacerbating myocardial rep	24
In vitro procoagulant effects of Gla-domainless factor Xa in factor XI-deficient and factor IX-deficient plasma	24
Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply ‘hyperfibrinolysis’	23
Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review	23
Sex disparities of clinical manifestations in acute pulmonary embolism and predictive value for in-hospital mortality: Insights from CURES	22
Canadian Perspective on Superficial Vein Thrombosis in Pregnancy and Postpartum: Interim Results from a Tertiary Care Centre	22
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis	22
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results	22
Control of warfarin treatment in patients with antiphospholipid syndrome and falsely high INR at point-of-care-testing	22
Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura	22
Driver gene KRAS aggravates cancer-associated stroke outcomes	22
Identification of phenotypes and predictors for dyspnea, echocardiographic probability of pulmonary hypertension, and confirmed CTEPH in patients with acute pulmonary embolism: Analysis of two large p	22
Predicting functional outcomes after acute ischemic stroke – Is thrombelastography useful outside perioperative bleeding management?	21
PO-22: Rate of venous thromboembolism events in cancer patients treated by radiation therapy: the Radiation-Induced Thrombosis study	21
CT coronary calcium score is a prognostic marker in acute pulmonary embolism	20
PO-18: Myocardial infarction and risk of cancer	20
PO-60: Comparison of inferior vena cava (IVC) filter use and outcomes between cancer and non-cancer patients in a single-center cohort	20
Platelets activated by different agonists produce microparticles with the same procoagulant properties	20
To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin	20
Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban	20
Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer	19
Preface to the Proceedings of the 11th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2022	19
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?	19
Safety of fixed-dose heparin titration boluses in underweight patients	19
Corrigendum to “Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism” [Thromb. Res. 193 (2020) 160–165]	19
Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism	19
PO-56: Low molecular weight heparin beyond 12 months in patients with cancer associated thrombosis: CAT-LONG study	19
PO-40: Therapeutic approaches of superior vena cava syndrome in patients with non-small cell lung cancer (NSCLC)	19
D-dimer as a predictive biomarker for cancer-associated thrombosis: A prospective cohort study	19
Risk factors for thrombocytopenia in adult patients with sepsis: A systematic review and meta-analysis	18
Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome	18
Real-time risk stratification in acute pulmonary embolism: the utility of RV/LV diameter ratio	18
Editorial Board	18
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry	18
Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: A systematic review	18
A comprehensive review of the autoimmune pathogenesis of acquired hemophilia A	18
Letter to the editor regarding the article “Platelet activity, coagulation, and fibrinolysis in long-term users of anabolic-androgenic steroids compared to strength-trained athletes”	18
The role of platelets in heat-related illness and heat-induced coagulopathy	18
Comparison of absolute immature platelet count to the PLASMIC score at presentation in predicting ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura	18
Pulmonary embolism bleeding score index (PEBSI): A new tool for the detection of patients with low risk for major bleeding on thrombolytic therapy	17
Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors	17
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia	17

Optimal enoxaparin dosing strategies for venous thromboembolism prophylaxis and treatment of high body weight patients	17
Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes	17
Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study	17
Clinical and genetic features of Chinese pediatric patients with severe congenital protein C deficiency who first presented with purpura fulminans: A case series study and literature review	17
Thrombin generation assay in venous thromboembolism: A scoping review	17
Editorial Board	16
Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism	16
Abstracts from the CanVECTOR 2024 Annual Conference October 25th, 2024	16
Editorial Board	16
Hsa_circ_0001020 accelerates the lower extremity deep vein thrombosis via sponging miR-29c-3p to promote MDM2 expression	16
Anticoagulation plus antiplatelet therapy versus anticoagulation alone following iliac vein stent implantation in acute and subacute deep vein thrombosis: A multicenter study with propensity score mat	16
Rotational thromboelastometry as a biomarker for mortality — The Maastricht Intensive Care COVID cohort	16
Procoagulant phenotype induced by oxidized high-density lipoprotein associates with acute kidney injury and death	16
OC-10: Plasmatic von Willebrand factor encapsulates blood circulating melanoma cells to prevent their hematogenous metastasis	15
Risk of venous thromboembolism in women with endometriosis	15
Barriers and facilitators for adherence to direct oral anticoagulants in patients with atrial fibrillation: A qualitative approach	15
Intracoronary antithrombotic therapy during primary percutaneous coronary intervention in patients with STEMI: A systematic review and network meta-analysis	15
Thromboelastography as a predictor of functional outcome in acute ischemic stroke patients undergoing endovascular treatment	15
Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase	15
Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination	15
Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial	15
Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study	15
Association between the simplified Pulmonary Embolism Severity Index (sPESI) score and hospitalization in emergency department patients diagnosed with pulmonary embolism	14
The long haul COVID-19 arterial thrombosis	14
Evaluation of modified pediatric sepsis-induced coagulopathy score in pediatric septic shock	14
Editorial Board	14
A noncanonical splicing variant c.875-5 T > G in von Willebrand factor causes in-frame exon skipping and type 2A von Willebrand disease	14
Effect of lupus anti-coagulant and antiphospholipid antibodies on clot waveform analysis parameters	14
Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials	14
Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis	14
Optimizing therapeutic enoxaparin in preterm neonates and infants	14
SSA-sMLP: A venous thromboembolism risk prediction model using separable self-attention and spatial-shift multilayer perceptrons	14
Stroke mortality in cancer survivors: A population-based study in Japan	14
Accuracy of physical examination in detecting central venous catheter-associated thrombosis in critically ill children	14
The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study	13
A Predictive Model to Identify Pulmonary Embolism in Unselected Emergency Department Patients: Model Validation and Improvement During the COVID Era	13
Acquired von Willebrand syndrome secondary to lymphoproliferative disorders: A case series from two French centers	13
18F-Fluorodeoxyglucose positron emission/computed tomography for occult cancer among patients with unprovoked venous thromboembolism: What do we know?	13
Long-term recurrence, bleeding, and mortality after first-time subsegmental pulmonary embolism compared to more proximal pulmonary embolism: Findings from the TROLL registry	13
Performance of age-adjusted and fixed threshold D-dimer to exclude DVT in those with low pre-test probability – Single centre experience	13
Postoperative myocardial injury and platelet reactivity in patients undergoing vascular surgery: The platelet reactivity and postoperative myocardial injury after major vascular surgery (PROMISE) stud	13
Letter: In response to a recent letter by Prior et al.	13
Incidence and impact of venous thromboembolism in hospitalized patients with Crohn's disease	13
Contact activated kallikrein generation is reduced six months after gastric bypass	13
PO-30: Chemotherapeutic agents temozolomide and lomustine induce procoagulant activity of glioblastoma cell lines in vitro	13
PO-23: Upper extremity deep vein thrombosis in cancer patients: our experience	13
Elevated plasma levels of factor VIII enhance arterial thrombus formation on erosive smooth muscle cell-rich neointima but not normal intima in rabbits	13
PO-54: Preliminary evaluation of venous thromboembolic risk in patients with colorectal cancer from the CARTAGO study	12
Covid-19 vaccination, adverse events, and detection of antibodies	12
Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting	12
Critique and advice of a multicenter mechanical thrombectomy registry in intermediate-risk PE	12
Trends in ischemic heart disease and thromboembolism-related mortality in the United States, 1999–2024: A population-based analysis using CDC WONDER Data	12
Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study	12
Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients	12
DOACs plasma levels in relation to clinical outcome. How far have we come?	12
Reference values of coagulation assays performed for thrombophilia screening after a first venous thrombosis and their intra-patient associations	12
Protein disulfide isomerase 1 (PDIA1) regulates platelet-derived extracellular vesicle release	12
Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: A report from the children's hospital acquired thrombosis (CHAT) consortium	12
Recurrent mechanical prosthetic valve thrombosis: Another clinical challenge	12
Outcomes of IVF treatments in women with antiphospholipid antibodies or antiphospholipid syndrome	12
Association between coagulation activity and clinical and imaging outcomes in acute ischemic stroke patients - A sub-study of the MR CLEAN NO-IV trial	12
Thrombocytopenia is associated with a dysregulated host response in severe COVID-19	12
PO-37: A study of the evolution of radiological features of untreated small volume pulmonary embolism (PE) in cancer patients	12
ROS-driven structural and functional fibrinogen modifications are reverted by interleukin-6 inhibition in Giant Cell Arteritis	12
Extracellular histones promote retraction and impair lysability of platelet-rich clots	12
The Attend-PE model: A feasibility study of a structured follow-up care model for patients with pulmonary embolism.	12
Risks of bleeding and thromboembolic events in patients undergoing colonoscopy on uninterrupted and interrupted anticoagulant therapy in real-world setting	12
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	11
Performance of the 4-Level Pulmonary Embolism Clinical Probability Score (4PEPS) in the diagnostic management of pulmonary embolism: An external validation study	11
DOAC Score for prediction of major bleeding in patients with venous thromboembolism: Findings from the RIETE registry	11
Hemostatic considerations for gender affirming care	11
The course of pulmonary embolism in individuals recovered from COVID-19	11
Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy	11
Editorial Board	11
Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation	11
Venous thromboembolism in women with hormone-dependent breast cancer. To continue or discontinue hormonal treatment? Insights from the RIETE registry	11
PO-29: Coagulation and circulating tumour cells as pharmacodynamic biomarkers of response to aromatase inhibitors in breast cancer	11
Trends of hospital admissions due to acute limb ischemia and venous thromboembolism in Austria: A population-wide observational analysis from 2009 to 2023	11
A systematic review and meta-analysis of periprocedural bridging for patients with mechanical heart valves undergoing non-cardiac interventions	11
PO-47: Prevention and treatment of recurrent trombosis after reconstruction of major vessels	11

Identification of two de novo variants causing inherited antithrombin deficiency by quantitative analysis of variant alleles	11
Platelets provide robustness of spatial blood coagulation to the variation of initial conditions	11
Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study	11
Increased contact system activity three months after starting combined oral contraceptives	11
The contact system in chronic kidney disease and hemodialysis – A cross-sectional study	11
Thymidine phosphorylase mediates SARS-CoV-2 spike protein enhanced thrombosis in K18-hACE2TG mice	11
PO-63: Edoxaban effect in a breast cancer patient with liver arterial infusion chemotherapy (LAIC) and both jugular vein and hepatic artery thrombosis: a unique clinical case	11
Challenging anticoagulation cases: A case of heparin-induced-thrombocytopenia in the first trimester of pregnancy	11
PO-57: Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients	11
Editorial Board	11
Treating the mind and body: implementation of a psychosocial wellbeing assessment in the deep vein thrombosis clinic	11
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial	10
Mitochondrial DNA copy number and its association with venous thromboembolism in patients with cancer	10
Perinatal stroke and hypofibrinogenemia: Is the new missense fibrinogen variant γ p.Gly310Glu the cause of the procoagulant state?	10
Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? – A population pharmacokinetic analysis	10
CXCL13/CXCR5 axis facilitates TFH expansion and correlates with disease severity in adults with immune thrombocytopenia	10
Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment	10
Identification of hematuria with a natural language processing model and validation of hematuria diagnosecodes	10
Characteristics and outcome of a territory-wide cohort study of patients with acquired hemophilia A in Hong Kong	10
Differential regulation of human thrombospondin-1 upon systemic desmopressin versus endotoxin challenge	10
Added IMPACT: The first successful natural birth using certolizumab in obstetric APS	10
Management strategies and clinical outcomes of venous thromboembolism in patients with antiphospholipid syndrome in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2	10
Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion	10
Neutrophil extracellular traps formation may be involved in the association of propranolol with the development of portal vein thrombosis	10
Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER)	10
Machine learning prediction of venous thromboembolism after surgeries of major sellar region tumors	10
Shiga toxin down-regulates ERG protein in endothelial cells and impairs angiogenesis	10
Who are we bridging? Description of warfarin patients receiving injectable bridging therapy	10
Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: A systematic review and meta-analysis	10
Molecular basis of clot retraction and its role in wound healing	10
Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis	9
A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab	9
Incidence and risk factors of post-thrombotic syndrome in patients with isolated calf vein thrombosis. Findings from the GARFIELD-VTE registry	9
Characterization of a prothrombotic phenotype using thrombin generation and thrombin activity in cirrhosis and portal hypertension	9
Dynamics of troponins and 30-day mortality in hospitalized patients with pulmonary embolism	9
Disulfide bond control of platelet αIIbβ3 integrin	9
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Correspondence	9
Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY	9
Erythrocyte rheology is altered in haemophilia patients with advanced arthropathy. A case-control study	9
CIB1 and platelet integrin αIIbβ3: Molecular mechanisms, disruption strategies and antithrombotic opportunities	9
PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer	9
Prognostic value of an automated thrombin generation assay in COVID-19 patients entering hospital: A multicentric, prospective observational study	9
Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis	9
COVID-19 associated Venous Thromboembolism (VTE) burden in Black women: Findings of Veterans Affairs COVID-19 Shared Data	9
Every 6 seconds in Europe	9
Prognosis after cerebral venous thrombosis: Mortality during initial admission and at 30 days and one year after discharge in a large Canadian population-based cohort	9
Natural history of untreated acute pulmonary embolism in patients with cancer: A retrospective cohort of missed pulmonary emboli	9
Association of antithrombotic medications and composition of thrombi retrieved by mechanical thrombectomy in acute ischemic stroke	9
Editorial Board	9
Scoping review of current evidence on the incidence of Venous thromboembolism (VTE) in the East Asian population	9
Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer	9
PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis	9
Prognostic role of serial electrocardiographic changes in patients with acute pulmonary embolism. Data from the Italian Pulmonary Embolism Registry	9
Osimertinib-related venous thromboembolism in non small lung cancer	8
Depression and anxiety up to two years after acute pulmonary embolism: Prevalence and predictors	8
JAK2V617F-positive extracellular genomic materials drive endothelial inflammation and thrombosis in myeloproliferative neoplasms	8
Outcomes of isolated distal thrombosis managed with serial compression ultrasonography	8
Copyright	8
Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study	8
Editorial Board	8
Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome	8
Long term recovery of right ventricular function after treatment of intermediate and high risk pulmonary emboli	8
Thrombectomy in high-risk pulmonary embolism – device versus thrombolysis: rationale and design of the TORPEDO-NL investigator-initiated, academically-sponsored, multicenter, open-label randomized con	8
In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project	8
The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: An Italian perspective	8
Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer	8
DOAC drug levels: Does “knowing” lead to safer care?	8
Effect of regular exercise training on platelet function in patients with cardiovascular disease and healthy individuals: A systematic review	8
Dielectric blood coagulometry to evaluate coagulation activity in patients prescribed factor Xa inhibitors undergoing elective surgery: A prospective observational study	8
COVID-19 venous thromboembolism prophylaxis guidelines in pediatrics	8
Anti-Xa Levels with Venous Thromboembolism Prophylaxis in Critical Care: A Systematic Review and Meta-Analysis	8
Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis	8
Development and validation of a clinical prediction model for post thrombotic syndrome following anticoagulant therapy for acute deep venous thrombosis	8
Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors	8
Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies	8
Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated pro	8
Editorial Board	8
Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?	8
Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism	8
Clinical and endoscopic findings in patients with acute gastrointestinal bleeding associated with direct oral anticoagulants: Results from a single-center prospective cohort study	8
Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies	8
Editorial Board	8
Exploration of rotational thromboelastometry (ROTEM) to characterize the coagulation profiles of newly diagnosed pediatric leukemia patients	8
Modest performance of risk-prediction models for anticoagulant-related bleeding in patients with chronic liver disease	7
Prolonged duration of pharmacological thromboprophylaxis following oncologic surgery: A systematic review and meta-analysis of RCTs	7
Late venous thromboembolism in survivors of adolescent and young adult cancer: A population-based study in California	7
Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE)	7
Reply to the letter to the editor ‘Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review’ by Frere et al.	7
Risk of bleeding in pulmonary embolism patients concomitant with COVID-19 undergoing extended anticoagulation: A multicenter cohort study	7
Oral anticoagulants and cognitive impairment in patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis	7
Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism	7
Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study	7
Clinical prediction tool to identify children at risk of pulmonary embolism	7
Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis	7
Blood group non-O is not associated with long-term adverse outcomes in patients undergoing percutaneous coronary intervention	7